2411019-98-0
Chemical Structure
PROTAC CDK9 degrader-14
- CAS No.: 2411019-98-0
- Formula:C42H53N9O6
- Molecular Weight:779.93
IUPAC Name: 8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)-N-(4-(((8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)octanamide
InChIKey: WFRJZAATGZSBLF-UHFFFAOYSA-N
SMILES: O=C1C2=C(CN1C3CCC(NC3=O)=O)C(OCCCCCCCC(NC4=CC=C(CNC5=NC(OC6CCN(CC6)C)=NC7=C(C(C)C)C=NN57)C=C4)=O)=CC=C2
Biological Activity: PROTAC CDK9 degrader-14 is a CDK9 PROTAC degrader that recruits CRBN. PROTAC CDK9 degrader-14 efficiently degrades CDK9 and inhibits cell proliferation in solid tumors and hematological malignancies. PROTAC CDK9 degrader-14 can be used in research related to solid tumors, hematological malignancies and triple-negative breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PROTAC CDK9 degrader-14 | PROTAC CDK9 degrader-14 is a CDK9 PROTAC degrader that recruits CRBN. PROTAC CDK9 degrader-14 efficiently degrades CDK9 and inhibits cell proliferation in solid tumors and hematological malignancies. PROTAC CDK9 degrader-14 can be used in research related to solid tumors, hematological malignancies and triple-negative breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chen, X, et al. Degradation agents for cyclin dependent kinase, preparation method thereof, pharmaceutical composition thereof and use thereof. WO2020035049A1. WIPO. 20.02.2020.
- [2]. Wei D, et al. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer. Journal of medicinal chemistry. 2021 Oct 14;64(19):14822-14847. [Content Brief]